HeartBeam Inc. (NASDAQ: BEAT) announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG patch in approximately 50 patients with suspected coronary artery disease at two hospitals in Belgrade, Serbia. The study represents a strategic step toward regulatory approval for a device that could expand ambulatory cardiac monitoring beyond rhythm assessment into ischemia detection, targeting an established approximately $2 billion patch-based monitoring market.
The study will compare synthesized 12-lead ECG readings generated by the company’s patch immediately following exercise stress testing against standard 12-lead ECGs. This comparison is critical for HeartBeam’s regulatory strategy, as the device is designed to provide on-demand ECG monitoring for patients outside medical facilities. If successful, the patch could enable physicians to identify cardiac health trends and acute conditions, directing patients to appropriate care without requiring a hospital visit.
HeartBeam’s technology is unique in that it is the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. The company holds over 20 issued patents related to its technology enablement. The 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025.
“This pilot study is a key milestone in our mission to transform cardiac monitoring,” said a company representative. The implications of this device are significant: if cleared, it could allow patients to monitor their heart health continuously or on-demand from home, potentially reducing hospital visits and enabling earlier detection of ischemia—a condition where blood flow to the heart is reduced, often leading to heart attacks.
The market for patch-based cardiac monitors is substantial, estimated at $2 billion, and is currently dominated by devices that primarily focus on rhythm detection. HeartBeam’s patch could carve out a new niche by adding ischemia detection, addressing a critical unmet need. For patients with coronary artery disease, this could mean faster intervention and better outcomes.
For more details, the full press release is available at https://ibn.fm/x7016. The company’s newsroom provides latest updates at https://ibn.fm/BEAT. Cleared indications for use can be found at https://www.heartbeam.com/indications.
The pilot study’s results will be crucial for HeartBeam’s next steps, including potential FDA submissions for expanded indications. The company’s platform technology, designed for portable devices, aims to deliver actionable heart intelligence wherever the patient is, redefining cardiac health management. As HeartBeam advances its clinical program, the medical community and investors will be watching closely to see if this technology can deliver on its promise to expand the capabilities of ambulatory cardiac monitoring.
